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Abstract The presence of overt hepatic encephalopathy (HE)
is associated with structural, metabolic and functional changes
in the brain discernible by use of a variety of magnetic reso-
nance (MR) techniques. The changes in patients with minimal
HE are less well documented. Twenty-two patients with well-
compensated cirrhosis, seven of whom had minimal HE, were
examined with cerebral 3 Tesla MR techniques, including T1-
and T2-weighted, magnetization transfer and diffusion-
weighted imaging and proton magnetic resonance spectrosco-
py sequences. Studies were repeated after a 4-week course of
oral L-ornithine L-aspartate (LOLA). Results were compared
with data obtained from 22 aged-matched healthy controls.
There was no difference in mean total brain volume between
patients and controls at baseline. Mean cerebral magnetization
transfer ratios were significantly reduced in the globus
pallidus and thalamus in the patients with cirrhosis irrespec-
tive of neuropsychiatric status; the mean ratio was significant-
ly reduced in the frontal white matter in patients with minimal
HE compared with healthy controls but not when compared
with their unimpaired counterparts. There were no significant
differences in either the median apparent diffusion coefficients
or the mean fractional anisotropy, calculated from the
diffusion-weighted imaging, or in the mean basal ganglia me-
tabolite ratios between patients and controls. Psychometric
performance improved in 50 % of patients with minimal HE
following LOLA, but no significant changes were observed in
brain volumes, cerebral magnetization transfer ratios, the dif-
fusion weighted imaging variables or the cerebral metabolite
ratios. MR variables, as applied in this study, do not identify
patients with minimal HE, nor do they reflect changes in psy-
chometric performance following LOLA.
Keywords Cirrhosis . Hepatic encephalopathy .Magnetic
resonance imaging . Spectroscopy
Introduction
It is widely accepted that the presence of minimal hepatic en-
cephalopathy (HE) has negative effects on quality of life and
survival (Weissenborn 2015). However, there is no universally-
accepted, robust and objective measure for determining its
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presence. The absence of such a measure is likely to hamper the
progress of therapeutic trials of medications that may be of
benefit to people with this condition. At present, the
Psychometric Hepatic Encephalopathy Score (PHES) battery
(Weissenborn et al. 2001) is considered to provide the best
clinical standard for evaluating cognitive function in patients
with cirrhosis, although testing can be time-consuming and
language-specific normative data are not available for all pop-
ulation subsets.
Cerebral magnetic resonance imaging (MRI) is a useful
tool for non-invasively assessing not only brain structure,
but also provides measures of cerebral volume and brain water
content. The techniques which have been utilized in patient
with HE include:
(i) Volumetric measurements: these have been applied in a
variety of clinical contexts including both minimal and
overt HE (McPhail et al. 2013; Patel et al. 2004).
(ii) Magnetization transfer imaging: several investigators
have reported reduced magnetisation transfer ratios
(MTR) in various regions of the brain in patients with
cirrhosis (Balata et al. 2003; Iwasa et al. 1999; Rai et al.
2015; Rovira et al. 2001; Taylor-Robinson et al. 1995).
Proposed mechanisms for this change in brain tissue
characteristics include alterations in astrocyte membrane
permeability and cytoplasmic structure and subsequent
shifts in the distribution of macromolecules and intracel-
lular water with an element of both subtle intracellular
oedema and an increase in extracellular fluid (Grover
et al. 2006). The reduction in MTR may reverse after
liver transplantation (Córdoba et al. 2001) and after treat-
ment for HE with rifaximin and lactulose (Rai et al.
2015), but there is no definitive evidence that the chang-
es observed relate to the presence or severity of HE.
(iii) Diffusion-weighted imaging (DWI): this allows non-
invasive probing of tissue ultrastructure, by quantifying
movement of water molecules. Two quantitative mea-
sures are derived from the diffusion data, namely the
apparent diffusion coefficient (ADC) and the fractional
anisotropy (FA).
The ADC is a measure of tissue water diffusivity; an increase
in ADC is regarded as indicating vasogenic or extracellular oe-
dema (Ebisu et al. 1993; Schaefer et al. 2000; Schwartz et al.
1998), while a reduction in ADC is interpreted as representing
cytotoxic or cellular oedema (Sotak 2004; van der Toorn et al.
1996). Studies in patients with cirrhosis and varying degrees of
HE have reported increased regional cerebral ADCs (Lodi et al.
2004; Sugimoto et al. 2008), with a degree of reversibility ob-
served following treatment for HE (Ahluwalia et al. 2014; Chen
et al. 2015; Kale et al. 2006). These findings have been attrib-
uted to: (i) increased brain water content (Lodi et al. 2004); (ii)
reversible interstitial oedema (Kale et al. 2006); (iii) minimal
cellular oedema with an increase in membrane permeability
and intracellular diffusivity, and changes in the viscosity of the
cytoplasm (Sugimoto et al. 2008).
Fractional anisotropy (FA) is a measure of the overall di-
rectionality of water diffusion. Chen et al. (2015) reported
significant reductions in mean FA throughout the cerebral
white matter in patients with minimal HE, compared to their
neuropsychiatrically unimpaired counterparts, but data from
healthy controls were not included for comparison. Ahluwalia
et al. (2015), reported significant increases in mean FA in
patents with minimal HE following 2 months of treatment
with rifaximin; however, no healthy controls were included
and so the FA data before treatment are not easily interpreted.
Lin and colleagues found no significant changes in mean FA
in 28 liver transplant candidates with minimal HE compared
with 30 healthy matched controls (Lin et al. 2014).
A reduction in FA in the corpus callosum has been reported
in people with a history of alcohol abuse, without apparent liver
disease, indicating that this may be an important confounder
(Pfefferbaum et al. 2006; Pfefferbaum and Sullivan 2002), al-
though the majority of patients included in the present study and
in the others reported to date had non-alcohol-related cirrhosis.
Cerebral proton magnetic resonance spectroscopy (1H
MRS) can be used to determine the biochemical profile of
an area of interest non-invasively. Several investigators have
reported characteristic spectral appearances in patients with
HE, including a reduction in the myo-inositol (mI) and choline
(Cho) resonances and an increase in the glutamine/glutamate
composite (GLx) resonance (Córdoba et al. 2001; Häussinger
et al. 1994; Laubenberger et al. 1997; Miese et al. 2006; Ross
et al. 1992; Taylor-Robinson et al. 1994, 1996). The generally
accepted explanation for these findings is that intracellular
osmolytes, such as mI, are expelled from astrocytes in order
to limit the degree of cell swelling which results from the
influx of excess ammonia and the subsequent accumulation
of osmotically active glutamine (Taylor-Robinson et al. 1996).
Although there is some evidence that cerebralMRmight be
useful to detect minimal HE (Chen et al. 2015; Rai et al. 2015)
and to determine the effects of treatment (Ahluwalia et al.
2014; Rai et al. 2015), relatively few well-controlled studies
are available, to date. The aim of this study was to determine if
measures of cerebral volume, water content and metabolite
concentrations, obtained using cerebral MR imaging and
spectroscopy, can be used to differentiate patients with mini-
mal HE from their neuropsychiatrically unimpaired counter-
parts and/or to monitor treatment effects.
Consecutive patients with cirrhosis with no current evi-
dence or past history of HE and a carefully matched healthy
control population underwent a combination of cerebral MR
techniques including:
1. MT to derive quantitative measures of brain water
content/membrane fluidity;
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2. DWI to assess intracellular and extracellular water and
structural integrity;
3. Volumetric imaging to determine brain volume;
4. 1H MRS to delineate the brain metabolite profiles.
Patients were reassessed and MR studies repeated in the
patients with cirrhosis after treatment for 4 weeks with oral
L-ornithine L-aspartate (LOLA), a specific ammonia lowering
agent.
Methods
Subjects
The patient population comprised of 22 right-handed individ-
uals (15 men: 7 women; mean age [range], 51 [37–65] years)
with biopsy-proven cirrhosis, recruited sequentially from
amongst those attending liver outpatient clinics at the
Imperial College Healthcare Trust, London. The aetiology of
the cirrhosis was alcohol in five (23 %); hepatitis C in five
(23 %); alcohol and hepatitis C in four (18 %); primary biliary
cirrhosis in three (14 %); autoimmune hepatitis and
haemochromatosis in two each (9 %) and hepatitis B in one
(5 %); all patients with alcohol–related liver disease had been
abstinent from alcohol for a minimum of 6 months before
participating. All 22 patient had well-compensated Child-
Pugh Grade A cirrhosis and were clinically stable at the time
of enrolment with no clinical evidence of neuropsychiatric
impairment. Patients were excluded from the study if they
had a history of cerebrovascular disease or of major psycho-
ses, type I diabetes, or type II diabetes with macrovascular
complications, renal impairment, hyponatraemia (serum sodi-
um <130 mmol/L), decompensated cardio-respiratory func-
tion, or were currently using illicit intravenous drug or taking
prescribed psychoactive medication. They were also excluded
if their manual dexterity was impaired or if they could not
speak English. None had contraindications to MRI scanning.
A total of 22, age-matched, right-handed, healthy volun-
teers (10 men: 12 women; mean age 47 [36–64] years) were
recruited from amongst visitors attending and staff working in
Imperial College Healthcare Trust. The same exclusion
criteria were applied when recruiting controls as when
recruiting the patients. In addition, individuals were excluded
if they drank alcohol in excess of National guidelines (16 g/
day for women and 24 g/day for men) or if they were taking
prescribed or over the counter medications. None had contra-
indications to MRI scanning.
Overall study design
All patients were comprehensively assessed at baseline in a
single session, lasting approximately 3 h, during which they
were clinically examined, blood was drawn for routine
haematology and chemistry and they underwent psychometric
testing and comprehensive MR scanning. Patients were then
prescribed 9 g/day of oral L-ornithine L-aspartate, in divided
doses, for 28 days following which the same procedures were
repeated.
The healthy controls underwent MR scanning using an
identical procedure to that adopted in the patients; scanning
was repeated in eight of the 22 controls after a median (range)
of 52 (46–56) days.
Psychometric testing
Psychometric testing was undertaken, by one of two individ-
uals (MMEC and VPBG), in a quiet room with constant light
level using the PHES battery (Weissenborn et al. 2001), which
comprises of five paper and pencil tests viz.: digit symbol,
number connection A and B, serial dotting and line tracing.
The PHES data were adjusted and scored using UK normative
data (Marks et al. 2008); composite scores of less than two
standard deviations below mean reference values were con-
sidered abnormal.
MR imaging: data acquisition and analysis
Cerebral MRI was performed on a 3 T Philips Intera™MR
system (Philips, Best, The Netherlands). Standard volumet-
ric imaging was performed using a T1-weighted three-
dimensional (3D) imaging sequence with the following ac-
quisition parameters: repetition time (TR) 256 ms, echo
time (TE) 3.8 ms, number of signal averages (NSA) 1,
256 image matrix, 25 cm field of view (FOV) and 2.0 mm
slice thickness. T2-weighted sequences were performed to
exclude structural brain pathology, with the following se-
quence parameters: TR 3000 ms, TE 80 ms, NSA 2, image
matrix of 230, 23 cm FOV, and 3.0 mm slice thickness.
DWI was obtained in 15 directions of sensitization using
single-shot echo planar imaging with the following se-
quence parameters: TR 12555 ms, TE 51 ms, slice thick-
ness 2 mm, NSA 2, b1000s/mm2. A SENSE factor of 2 was
used to reduce image distortion. MT was obtained using a
two-dimensional gradient-echo pulse sequence with the
following parameters: TR 54.7 ms, TE 3.75 ms, flip angle
15 degrees, slice thickness 2 mm, 1 NSA with 20 slices
positioned over the basal ganglia.
Brain volumes were calculated in FMRIB software library
(FSL v4.1, University of Oxford, UK), using SIENAX (www.
fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA) following guidance on
calculation algorithms provided by Klauschen et al. (2009).
Co-registration using the exterior skull surface to align images
prior to and following treatment was performed using the T1-
weighted images. The skull was then removed from the im-
ages using the brain extraction tool (BET) within the software
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package. Tissue class segmentation was then performed on the
images to calculate the total grey and white matter volumes
(excluding CSF). The fractional intensity threshold was set to
the default value of 0.35 and standard brain masking was
utilised.
MTR maps were calculated, using ImageJ® version 1.32j,
(www.imagej.nih.gov) using the formula:
MTR ¼ 100 SI0−SIRFð Þ=SI0;
where SIRF is the signal intensity in the image employing an
off-resonance RF pulse and SI0 the signal intensity in the
initial proton density image.
Regions of interest (ROIs) were drawn around: (i) the fron-
tal white matter; (ii) the head of the caudate; (iii) the putamen;
(iv) the globus pallidus; and, (v) the thalamus bilaterally.
Standardized areas within the ROIs were used for compari-
sons of data between subjects.
ADC and FA maps were calculated from the DWI data sets
using DTI Studio version 2.1 (www.dsi-studio.labsolver.org).
ADC and FA values were recorded from specific ROIs in the
genu, body and splenium of the corpus callosum. These areas
were chosen as they were anatomically highly conspicuous
and hence easily defined on this imaging sequence.
Standardized areas within the ROIs were used for
comparisons of data between subjects.
MR spectroscopy: data acquisition and analysis
1H MRS was acquired using a SENSE head coil and a short
echo time PRESS sequence with the following parameters:
TR 2000 ms, TE 36 ms, NSA 64, with volumes of interest
of 15 × 15 × 15 mm placed in the left basal ganglia. The
sequence was performed three times to give a total NSA of
192.
1H MR spectra were analyzed by two observers (MW and
LS), blinded to the clinical status of the subjects. Peak areas
were measured for choline-containing compounds (Cho),
creatine/phosphocreatine (Cr), myo-inositol (mI), glutamine/
glutamate (Glx) and N-acetylaspartate (NAA), using the
‘Advanced Method for Accurate, Robust and Efficient
Spectral Fitting of MRS Data’ (AMARES) algorithm, includ-
ed in the jmrui software package (www.jmrui.eu), in the time
domain. Peak area ratios for NAA/Cr, Cho/Cr, Glx/Cr and
mI/Cr were then calculated as previously reported (McPhail
et al. 2013).
Statistical methods
Data were tested for normality using the Shapiro-Wilk test.
Between-group comparisons were made with the Mann-
Whitney U test or Kruskall Wallis test with Dunn’s correction
for multiple comparisons. Longitudinal data were analysed
using the Wilcoxon signed rank sum test. Correlations were
made with the Spearman rank test. Tests of significance were
two-tailed. Statistical analyses were performed using SPSS
version 16 (SPSS Inc., USA). Where multiple brain regions
were analyzed, a multiple correction factor of n-1 was applied.
The relationships between continuous MR variables (MTR,
ADC and spectral intensities) were examined using
Pearson’s r with a false discovery rate modification of the p
value for significance of <0.005.
Ethics
Ethical approval was obtained from the joint Hammersmith
Hospital/Queen Charlotte’s & Chelsea Hospital Research
Ethics Committee (ref 04/Q0406/161), London, UK. Local
Research Governance approval and indemnity was provided
by Imperial College London. All subjects provided written
informed consent.
Results
Baseline psychometric status
At baseline, seven (32 %) of the 22 patients with cirrhosis
were classified as having minimal HE, based on the results
of the PHES test battery, while the remaining 15 patients were
classified as neuropsychiatrically unimpaired.
Baseline MR variables
Baseline cerebral imaging variables were available in 22 pa-
tients and 22 control subjects. MRS variables were available
in 20 patients and 22 controls.
Brain volume
There was no significant difference in total brain volume be-
tween patients and healthy controls.
Magnetization transfer ratios
Mean MTRs were significantly reduced in the frontal white
matter (1.8 %), globus pallidus (3.7 %) and thalamus
(2.1 %) in the patients with cirrhosis, compared to the
healthy controls (Table 1). There were no differences in
the reductions in MTRs in the globus pallidus and thala-
mus in relation to neuropsychiatric status, whereas the re-
duction in mean frontal white matter MTR was only ob-
served in the patients with minimal HE (Fig. 1). However,
there was no significant difference between frontal white
matter MTR in the patients with minimal HE and their
unimpaired counterparts.
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Diffusion weighted imaging
The median ADC in the body of the corpus callosum was
increased in the patients with cirrhosis, compared to healthy
controls, but the difference was not significant (Table 1). The
median ADCs in the two other studied regions of the corpus
callosum were comparable between the two groups (Table 1).
There were no significant differences in median ADC in rela-
tion to neuropsychiatric status.
There were no significant differences in the mean FA in the
three regions of the corpus callosum between patients and
controls (Table 1). There were no significant differences in
mean FA in relation to neuropsychiatric status.
Magnetic resonance spectroscopy
There were no significant differences in mean basal ganglia
metabolite ratios between patients and controls (Table 1).
Correlation analysis
Significant positive correlations were observed between
MTRs in the ROIs (r = 0.823 (putamen v globus pallidus);
r = 0.720 (putamen v frontal white matter), p < 0.001 for both)
but otherwise there were no significant correlations between
ADC,MTR and spectroscopic intensities following correction
for multiple comparison (Supplementary Figure and Table).
Psychometric testing following LOLA
Psychometric performance, assessed using the PHES battery,
improved in four of the seven patients with minimal HE fol-
lowing LOLA. No changes were observed in psychometric
performance in the remaining patients.
MR variables following LOLA
Follow-up MR scans were undertaken in eight of the 22
healthy controls. No differences were observed in any of the
measured MR variables.
Brain volume
Twenty pairs of pre- and post-LOLAT1 brain volume datasets
were available for analysis. There was insufficient contrast in
the caudal regions of the brains in the remaining two datasets
which would have resulted in unreliable tissue segmentation/
edge-finding. There was no differential change in global or
regional brain volume in relation to or neuropsychiatric status
or LOLA responsiveness.
Table 1 Baseline MR imaging
and spectroscopy variables in
patients with cirrhosis and healthy
controls
MRVariable Healthy controls (n = 22) Patients with cirrhosis (n = 22) Significance (p)
Magnetization Transfer Ratio
Frontal WM 57.5 (57.0–58.0) 57.0 (55.7–57.4) 0.023
Caudate 47.0 (46.6–47.6) 46.8 (45.7–47.6) 0.545
Putamen 48.7 (47.9–49.0) 48.2 (47.3–48.9) 0.147
Globus pallidus 53.4 (52.9–53.7) 51.4 (50.5–52.6) 0.001
Thalamus 53.0 (52.3–53.5) 51.5 (50.5–51.9) <0.001
DWI: Corpus Callosum: ADC (10–3 mm2/s)
Genu 0.83 (0.79–0.87) 0.82 (0.808–0.843) 0.763
Splenium 0.72 (0.70–0.75) 0.72 (0.71–0.77) 0.951
Body 0.80 (0.75–0.82) 0.83 (0.80–0.84) 0.088
DWI: Corpus Callosum: FA
Genu 0.74 ± 0.05 0.75 ± 0.03 0.647
Splenium 0.86 ± 0.06 0.85 ± 0.04 0.608
Body 0.73 ± .0.03 0.75 ± 0.04 0.051
1H-MRS Left Basal Ganglia
NAA/Cr 1.30 ± 0.21 1.55 ± 0.51 0.096
Cho/Cr 0.81 ± 0.17 0.79 ± 0.23 0.745
mI/Cr 0.35 ± 0.11 0.42 ± 0.21 0.173
Glx/Cr 0.77 ± 0.28 1.05 ± 0.47 0.081
Data expressed as mean ± 1SD or as median (interquartile range)
Bold highlights the p values that are statistically significant
DWI Diffusion Weighted Imaging, ADC Apparent Diffusion Coefficient, FA Fractional Anisotropy, NAA N-
acetylaspartate, Cr creatine, Cho choline, mI myo-inositol, Glx-glutamine/glutamate
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Magnetization transfer ratios
There were no significant differences in median cerebral
MTRs following LOLA in the patient group as a whole
(Table 2). No post-LOLA differences were observed in
MTRs in the patients by neuropsychiatric status or LOLA
responsiveness.
Diffusion weighted imaging
There was no significant difference in mean cerebral
ADCs or mean cerebral FA in patients following LOLA,
either in the group as a whole (Table 3) or in the sub-
groups defined by neuropsychiatric status or LOLA
responsiveness.
*
* *
****
Caudate
C
o
n
tr
o
ls
N
o
 M
H
E
M
H
E
40
45
50
55
60
Putamen
M
T
R
 
/
 
%
C
o
n
tr
o
l
N
o
M
H
E
M
H
E
40
45
50
55
60
Globus
C
o
n
tr
o
ls
N
o
 M
H
E
M
H
E
40
45
50
55
60
Thalamus
C
o
n
tr
o
ls
N
o
 M
H
E
M
H
E
40
45
50
55
60
Frontal white matter
C
o
n
tr
o
ls
 (
n
=
2
2
)
N
o
M
H
E
 (
n
=
1
5
)
M
H
E
(n
=
7
)
40
45
50
55
60
Fig. 1 Regional cerebral
Magnetisation Transfer Ratios in
healthy controls and in patients
with cirrhosis, by
neuropsychiatric status. Data are
presented as median (IQR).
Significance of the difference
from healthy controls *p < 0.05,
**p < 0.01, ***p < 0.001
Table 2 Regional cerebral magnetization transfer ratios in patients with
cirrhosis pre- and post-LOLA
Brain region Magnetization Transfer Ratio Significance (p)
Pre-LOLA
(n = 22)
Post-LOLA
(n = 22)
Frontal WM 57.0 (55.7–57.4) 56.5 (56.0–57.3) 0.85
Caudate 46.8 (45.7–47.6) 46.1 (45.6–47.7) 0.44
Putamen 48.2 (47.3–48.9) 47.8 (47.3–49.1) 0.95
Globus pallidus 51.4 (50.5–52.6) 51.5 (50.1–52.0) 0.58
Thalamus 51.5 (50.5–51.9) 51.2 (50.4–51.8) 0.48
Data expressed as median (interquartile range)
WM white matter
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Magnetic resonance spectroscopy
The coefficient of variation for NAA/Cr was 0.041 with a vari-
ability of 1 % between the first and tenth scans. The coefficient
of variation for Cho/Cr was 0.098 with a variability of 4.35 %.
Therewas no significant difference in themeasured basal ganglia
metabolite ratios in the patients with cirrhosis following LOLA
or in sub-groups of patients defined by neuropsychiatric status or
LOLA responsiveness. There were no significant associations
between the MRS data derived from the putamen, globus
pallidus and thalamus and the Cho/Cr in the basal ganglia.
Discussion
This study was designed to investigate whether measures of
cerebral volume, water content and metabolite concentrations,
obtained using cerebral MR imaging and spectroscopy, could
be used to differentiate patients with minimal HE from their
neuropsychiatrically unimpaired counterparts and/or to monitor
the effects of measures designed to change neuropsychiatric
status. LOLA, an ammonia–lowering agent, which has been
used to treat HE (Fleig et al. 1999; Poo et al. 2006; Stauch
et al. 1998), was given to all patients, irrespective of neuropsy-
chiatric status, because the purpose of the study was not to
demonstrate the efficacy of this agent as a treatment, but to
use it as a therapeutic tool to effect change in psychometric
performance, and thus determine if the MR sequences under
investigation were sufficiently sensitive to detect change within
the brain that might correlate with the psychometric changes.
Good quality cerebral MR data were obtained, using a 3 T
system, from well-characterised populations of patients with
cirrhosis and matched healthy controls. However, no definitive
baseline MR features were observed that either distinguished
the patients from the controls, or effectively differentiated the
pat ients with minimal HE from those who were
neuropsychiatrically unimpaired. Four of the seven subjects
(50 %) classified as having minimal HE, at baseline, showed
improvement in psychometric performance, to within the nor-
mal range, following 4 weeks of LOLA, but this was not ac-
companied by any significant changes in MR variables overall.
The significant positive correlations observed between re-
gional cerebral MTRs values suggest that the abnormalities of
water distribution are widespread. Biochemical and white
matter (tractography) abnormalities are not well correlated
suggesting that the more functional aspects of interconnectiv-
ity may be more localized. This is supported by previous find-
ing in this population in relation to the default mode network
(McPhail et al. 2013).
One of the limitations of the study is the relatively small
number of patients with minimal HE. This was undoubtedly a
feature of the recruitment procedures as consecutive eligible
patients, with no evidence of clinical HE, were selected from
amongst ‘well’ out-patients with cirrhosis and they only
underwent psychometric testing once selected. However, pa-
tients with cirrhosis with possible confounding or co-
occurring condition which might affect their cerebral function
were excluded and the study was controlled.
The results of the present study both support and contradict
previous findings. Thus, in this study mean MTRs were signif-
icantly reduced in the frontal white matter, globus pallidus and
thalamus in patients with cirrhosis, compared to healthy con-
trols and were lower in the frontal white matter in the patients
with minimal HE, compared to the controls but not to their
unimpaired counterparts. In addition, there was no significant
difference between MTRs before and after LOLA, even in
those patients in whom psychometric performance improved.
Other studies have demonstrated reversibility of cerebral
MTRs after liver transplantation (Córdoba et al. 2001) and after
treatment with rifaximin and lactulose (Rai et al. 2015).
However, in the present study, both the level of psychometric
impairment and severity of liver disease were subtler than in
previous studies. Thus, the magnitude of baseline abnormalities
may be less pronounced compared to those in patients withmore
severe liver disease. Subsequently, the ability to detect a statisti-
cally significant change in, for example, MTR following an im-
provement in psychometric performance may be more limited.
A 15-directionDWI sequencewas used for data acquisition
in the present study, with ROIs in three regions of the corpus
callosum. These measurements demonstrated increased medi-
an ADCs in the body of the corpus callosum in patients with
cirrhosis, compared to healthy controls, but this did not reach
statistical significance after correction for multiple compari-
sons. An increase in ADCs may result from minimal cellular
oedema with an increase of membrane permeability and in-
creased intracellular diffusivity, as well as changes in the vis-
cosity of the cytoplasm (Lodi et al. 2004). The findings in the
present study contrast with those of Sugimoto and colleagues
who studied 24 healthy controls of mean age 62 ± 9 years and
Table 3 Cerebral diffusion weighted imaging variables in the corpus
callosum in patients with cirrhosis pre- and post-LOLA
Brain Region Patients with Cirrhosis Significance (p)
Pre-LOLA
(n = 21)
Post LOLA (n = 22)
Apparent Diffusion Coefficient (10–3 mm2/s)
Genu 0.82 (0.81–0.84) 0.83 (0.79–0.85) 0.93
Splenium 0.72 (0.70–0.77) 0.73 (0.70–0.76) 0.77
Body 0.83 (0.80–0.84) 0.81 (0.80–0.84) 0.37
Functional Anisotropy (0–1)
Genu 0.75 ± 0.03 0.74 ± 0.05 0.35
Splenium 0.85 ± 0.04 0.84 ± 0.05 0.99
Body 0.75 ± 0.04 0.74 ± 0.04 0.31
Data expressed as median (interquartile range) or mean ± 1SD
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10 subjects with cirrhosis and minimal HE of mean age
70 ± 6 years, the majority of whom had moderately decom-
pensated disease (Sugimoto et al. 2008). They reported in-
creased ADCs in the frontal and parietal white matter, but
found no statistically significant difference in the putamen,
globus pallidus or cingulate regions.
In the present study, there was no significant change in
median regional ADCs before and after oral LOLA in the
whole patient cohort or the sub-category of responders to
LOLA. This is not surprising, given the fact that there were
no differences in baseline ADC values between patients and
controls. However, these findings contrast with those of Kale
et al. (2006) who reported a significant reduction in ADCs in
the corpus callosum, right internal capsule, left internal cap-
sule, caudate nucleus, putamen, frontal and occipital white
matter in 10 patients with minimal HE treated with lactulose
for a total of 3 weeks. The functional severity of the liver
disease in this subgroup of 10 patients was not specified, but
the majority of the original cohort of 39 patients had decom-
pensated disease.
There were no significant differences in mean baseline ce-
rebral FA between healthy controls and the patients with cir-
rhosis in the present study and there were no changes follow-
ing LOLA, even in those who responded with an improve-
ment in psychometric performance. Ahluwalia and colleagues
reported significant increases in mean cerebral FA in 16 pa-
tients with minimal HE following 8 weeks of treatment with
rifaximin, during which time psychometric performance im-
proved significantly (Ahluwalia et al. 2014). However, the
interpretation of these results is confounded because no
healthy control data were provided. Chen and colleagues stud-
ied 65 patients with cirrhosis, 29 of whom had minimal HE,
while the remaining 36 had no evidence of neuropsychiatric
impairment (Chen et al. 2015). The mean FAwas significantly
reduced in multiple cerebral regions and the changes in FA
values were found, after adjustment for the degree of hepatic
dysfunction, to be predictive of survival over the next
18 months. Again, the absence of a healthy control group
hampers the interpretation of the data. Finally, Lin and col-
leagues found no significant changes in mean FA in 28 liver
transplant candidates with minimal HE, compared to 30
healthy, matched controls (Lin et al. 2014). However, studies
repeated 6 to 12 months following liver transplantation
showed a decrease in FA in the right temporal lobe which,
along with the changes observed in other imaging modalities
were attributed to demyelination and gliosis.
The overall interpretation of the DWI findings in the pres-
ent study and in the others undertaken to date is difficult.
Study protocols differ appreciably and so do the methods of
data analysis and the variables selected for study; thus direct
comparisons are difficult, if not impossible to make. Chen and
colleagues, for example, interpreted the increase they ob-
served in cerebral mean diffusivity (MD), in patients with
minimal HE, as indicating intracerebral oedema and the re-
duction in cerebral FA as reflecting impaired microstructural
integrity, but without further elaboration (Chen et al. 2015).
Ahluwalia and colleagues interpreted their findings, in pa-
tients with minimal HE, of an increase in cerebral FA follow-
ing treatment with rifaximin in the absence of any change in
cerebral MD as indicative of a treatment–related correction of
intracellular oedema (Ahluwalia et al. 2014). Finally, Lin and
colleagues interpreted the trend to an increase in cerebral MD
that they observed in patients with minimal HE, but with no
change in cerebral FA as perhaps indicating the co-existence
of extracellular and intracellular oedema (Lin et al. 2014). The
findings in the present study could be similarly explained.
1H MRS in patients with cirrhosis and minimal HE is nor-
mally typified by the finding of increased cerebral Glx/Cr and
reduced mI/Cr and Cho/Cr ratios (Córdoba et al. 2001; Miese
et al. 2006; Taylor-Robinson et al. 1996; Meng et al. 2015).
The choline resonance contains components from compounds
that participate in phospholipid metabolism and osmotic reg-
ulation in glial cells. The reduction in the Cho/Cr in patients
with cirrhosis is considered to represent osmolar changes in
the brain, whereas an elevated Cho/Cr is considered to repre-
sent myelin destruction, increased membrane synthesis or
neuroinflammation (Patel et al. 2012). mI is a sugar involved
in the synthesis of phosphoinositides for cerebral osmoregu-
lation. The main reservoir of mI is within the glial cells, thus it
is proposed to be a marker of glial cell osmoregulation. (Patel
et al. 2012).
The observation that the mean cerebral metabolite ratios
were unchanged in the patients with cirrhosis, in the present
study, was unexpected. This finding may reflect differences in
the MR scanning parameters and the selected ROIs between
studies. Thus, the present study was undertaken at a magnetic
field strength of 3 Twhereas most previous studies have been
conducted at 1.5 T. As MR visibility is sequence dependent it
was anticipated that with the inherent signal to noise advan-
tage of imaging at 3 T, it might be possible to better differen-
tiate and quantify individual metabolite peaks. Similarly, pre-
vious studies have provided MRS information from areas of
the brain such as the parieto-occipital cortex (Córdoba et al.
2001, 2002), deep white matter (Häussinger et al. 1994) and
the visual cortex (Laubenberger et al. 1997) whereas in this
study MRS information was provided from the basal ganglia,
where susceptibility effects related to manganese deposition
may have affected tissue properties resulting in changes in
relaxation times and ultimately on Cho/Cr or mI/Cr ratios.
This effect may be even more apparent at 3 T (Ochi et al.
2011).
In conclusion: changes in cerebral MTR are observed in
patient with cirrhosis, but with the exception of a reduction in
MTR in the frontal region none was specific for the presence
of minimal HE. Although four of seven patients with minimal
HE showed improvement in psychometric testing following
Metab Brain Dis
LOLA this was not reflected in any discernable changes in
MR variables. Based on this study it would not appear that
cerebral MRI or MRS have sufficient utility for the diagnosis
of minimal HE or the monitoring of treatment effects in this
patient group to recommend they use in routine clinical prac-
tice. Justification for use of these techniques in a research
setting should to be based on proof of diagnostic efficacy
obtained from a large multicenter trial utilizing strict protocol
standardization for MR data acquisition.
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